A multicenter randomized controlled trial (RCT) co-led by McMaster University has demonstrated that duloxetine, a widely available SNRI antidepressant, significantly reduces fatigue in adults with long COVID. The study (double-blind, placebo-controlled, n=348 participants across 12 sites) reported a 28% greater improvement in validated fatigue scales (FACIT-F) at 12 weeks compared to placebo. As an RCT with adequate powering and low attrition, this represents higher-quality evidence than the predominantly observational cohorts that have defined much of long COVID research to date. No pharmaceutical industry conflicts of interest were declared; the trial was funded through public health research grants.

Original coverage emphasized the 'breakthrough' framing but missed critical context: long COVID fatigue shares pathophysiological overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), including neuroinflammation and autonomic dysfunction. A 2022 Nature Medicine observational study (n=1,276 patients) documented persistent immune activation and microvascular changes months after infection, patterns also seen in post-EBV fatigue syndromes. Similarly, a large 2023 JAMA cohort analysis (n=9,764 U.S. adults) found 15% of COVID survivors experienced debilitating fatigue at six months, with minimal decline by two years, underscoring that this condition has not disappeared despite fading media attention.

The McMaster RCT's strength lies in repurposing an inexpensive, generic medication already used for fibromyalgia and depression, where fatigue is a core symptom. However, it also reveals limitations the original source underplayed: benefits were most pronounced in patients with moderate rather than severe fatigue, and 18% reported nausea or sleep disturbances. This aligns with broader patterns of post-viral syndromes where neuromodulators show moderate efficacy but rarely provide complete resolution alone.

Synthesizing these sources paints a clearer picture: while public discourse has shifted due to 'pandemic fatigue,' the economic and human costs persist, particularly for working-age adults. Duloxetine's mechanism—enhancing descending pain inhibition and serotonin/norepinephrine balance—may address central sensitization missed by purely antiviral or anti-inflammatory approaches. Clinicians should view this as a pragmatic tool within multimodal care, not a panacea, and prioritize shared decision-making given variable individual responses.